Astrazeneca (AZN) Receivables - Other (2009 - 2025)
Astrazeneca (AZN) posted quarterly Receivables - Other of $2.0 billion for Q4 2025, up 27.74% year-over-year from $1.6 billion in Q4 2024, and up 27.74% quarter-over-quarter from $1.6 billion in Q4 2024.
Astrazeneca (AZN) Receivables - Other (2009 - 2025) Analysis & Trends
Astrazeneca's Receivables - Other history runs 17 years deep, the most recent figure standing at $2.0 billion for Q4 2025.
- In Q4 2025, Receivables - Other rose 27.74% year-over-year to $2.0 billion; the TTM figure through Dec 2025 stood at $2.0 billion (up 27.74% YoY), while the FY2025 annual figure was $2.0 billion, up 27.74% from the prior year.
- Receivables - Other for Q4 2025 stood at $2.0 billion, up from $1.6 billion in the prior quarter.
- The five-year high for Receivables - Other was $3.5 billion in Q1 2021, with the low at $1.6 billion in Q4 2024.
- The 5-year median for Receivables - Other is $1.7 billion (2021), against an average of $2.0 billion.
- The sharpest annual moves came in 2021 and 2022: Receivables - Other jumped 41.47% in 2021, then decreased 8.24% in 2022.
- Astrazeneca's Receivables - Other stood at $1.8 billion in 2021, then decreased by 8.24% to $1.7 billion in 2022, then retreated by 1.21% to $1.6 billion in 2023, then fell by 3.66% to $1.6 billion in 2024, then rose by 27.74% to $2.0 billion in 2025.
- Business Quant data shows AZN's Receivables - Other at $2.0 billion in Q4 2025, $1.6 billion in Q4 2024, and $1.6 billion in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.02 Bn |
| Dec 31, 2025 | 2.02 Bn |
| Dec 31, 2024 | 1.58 Bn |
| Dec 31, 2024 | 1.58 Bn |
| Dec 31, 2023 | 1.64 Bn |
| Dec 31, 2023 | 1.64 Bn |
| Dec 31, 2022 | 1.66 Bn |
| Dec 31, 2022 | 1.66 Bn |
| Dec 31, 2021 | 1.81 Bn |
| Dec 31, 2021 | 1.81 Bn |
| Mar 31, 2021 | 3.49 Bn |
| Mar 31, 2021 | 3.49 Bn |
| Dec 31, 2020 | 1.28 Bn |
| Dec 31, 2020 | 1.28 Bn |
| Jun 30, 2020 | -1.40 Bn |
| Jun 30, 2020 | -1.40 Bn |
| Dec 31, 2019 | 1.08 Bn |
| Dec 31, 2019 | 1.08 Bn |
| Jun 30, 2019 | -1.34 Bn |
| Jun 30, 2019 | -1.34 Bn |